共 50 条
- [41] Sustained Minimal Residual Disease Negativity in Newly Diagnosed Multiple Myeloma (NDMM) Patients Treated with Carfilzomib (CFZ), Lenalidomide (LEN), and Dexamethasone (DEX) Followed By 2 Years of Lenalidomide Maintenance (CRd-R): Updated Results of a Phase 2 StudyBLOOD, 2016, 128 (22)Kazandjian, DickranKorde, Neha S.Roschewski, MarkMailankody, ShamMorrison, CandisManasanch, Elisabet E.Kwok, Mary L.Tageja, NishantBhutani, ManishaZingone, AdrianaCostello, ReneZhang, YongMulquin, MarciaLamping, LizCarpenter, AshleyRoberson, BrendaMaric, IrinaCalvo, Katherine R.Braylan, Raul C.Yuan, Constance M.Stetler-Stevenson, MaryaliceArthur, Diane C.Lindenberg, LizaKurdziel, Karen A.Choyke, PeterSteinberg, Seth M.Figg, WilliamWilson, Wyndham H.Landgren, Ola
- [42] Fixed Duration Combination Therapy with Carfilzomib, Lenalidomide, and Dexamethasone Followed By Lenalidomide Maintenance Leads to High Rates of Sustained MRD Negativity in Patients with High-Risk Smoldering Multiple Myeloma: Long Term Follow up of an Investigator Initiated Phase 2 TrialBLOOD, 2023, 142Hill, ElizabethRoswarski, Joseph L.Bhaskarla, AmritEmanuel, MichaelPetrosyan, AniWang, Hao-WeiYuan, Constance M.Lindenberg, LizaMena, EstherTurkbey, BarisPatel, NishaMaric, IrinaDulau-Florea, AlinaCalvo, KatherineBraylan, Raul C.Stetler-Stevenson, MaryaliceSteinberg, Seth M.Figg, WilliamKazandjian, Dickran
- [43] Final Results of a Frontline Phase 1/2 Study of Carfilzomib, Lenalidomide, and Low-Dose Dexamethasone (CRd) in Multiple Myeloma (MM)BLOOD, 2011, 118 (21) : 288 - 289Jakubowiak, Andrzej J.Dytfeld, DominikJagannath, SundarVesole, David H.Anderson, Tara B.Nordgren, Brian K.Detweiler-Short, KristenLebovic, DanielStockerl-Goldstein, Keith E.Griffith, Kent A.Jobkar, Terri L.Durecki, Diane E.Wear, Sandra M.Ott, Robert F.Al-Zoubi, AmmarMietzel, Melissa A.Hussein, M.Couriel, DanielLeveque, Joseph A.Vij, Ravi
- [44] Efficacy and safety of carfilzomib, lenalidomide, and dexamethasone versus ixazomib, lenalidomide, and dexamethasone in real world patients with relapsed/refractory multiple myeloma: KMM2004 studyCLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S189 - S190Kim, Do YoungShin, Ho-JinMin, Chang-KiEom, Hyeon-SeokJung, JongheonKim, KihyunLee, Jae HoonYoo, Kwai HanLee, Ji YunByun, Ja MinKim, Sung-HyunLee, Ji HyunCho, Hee JeongLee, Sang MinDo, Young RokPark, SungwooLee, JunglimLee, Seung-ShinKang, Hye JinPark, Young HoonLim, Sung-Nam
- [45] ECONOMIC EVALUATION OF CARFILZOMIB plus LENALIDOMIDE plus DEXAMETHASONE (KRD) VS LENALIDOMIDE plus DEXAMETHASONE (RD) IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (R/RMM)HAEMATOLOGICA, 2016, 101 : 526 - 526Fonseca, R.Panjabi, S.Campioni, M.Giannopoulou, A.Benedict, A.Houisse, I.Aggarwal, S.Jakubowiak, A.
- [46] Venous Thromboembolism Risk in Patients With Newly Diagnosed Multiple Myeloma Treated with Carfilzomib or Bortezomib in Combination With Lenalidomide and DexamethasoneCLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 (11): : 825 - 828Loncharich, Alexa J.Fiala, Mark A.Slade, Michael J.Vickroy, AngelaKavanaugh, MargaretWilson, CarmenSchroeder, Mark A.Stockerl-Goldstein, KeithVij, RaviSanfilippo, Kristen M.
- [47] EFFECT OF CARFILZOMIB, LENALIDOMIDE, AND DEXAMETHASONE VS LENALIDOMIDE AND DEXAMETHASONE IN PATIENTS WITH RELAPSED MULTIPLE MYELOMA BY LINE OF THERAPY: INTERIM RESULTS FROM THE PHASE 3 ASPIRE STUDYHAEMATOLOGICA, 2015, 100 : 151 - 152Dimopoulos, M. A.Stewart, A. K.Rajkumar, S. V.Masszi, T.Spicka, I.Oriol, A.Hajek, R.Rosinol, L.Siegel, D.Mihaylov, G. G.Goranova-Marinova, V.Rajnics, P.Suvorov, A.Niesvizky, R.Jakubowiak, A.San-Miguel, J.Ludwig, H.Zojwalla, N.Tonda, M.Yang, X.Moreau, P.Palumbo, A.
- [48] EXTENDED TREATMENT WITH THE COMBINATION OF CARFILZOMIB (CFZ), LENALIDOMIDE (LEN), AND DEXAMETHASONE ( DEX) IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM)HAEMATOLOGICA, 2012, 97 : 115 - 115Jakubowiak, A.Griffith, K.Dytfeld, D.Vesole, D.Jagannath, S.Anderson, T.Nordgren, B.Detweiler-Short, K.Lebovic, D.Stockerl-Goldstein, K.Jobkar, T.Wear, S.Al-Zoubi, A.Ahmed, A.Mietzel, M.Couriel, D.Kaminski, M.Hussein, M.Yeganegi, H.Vij, R.
- [49] Venous Thromboembolism Risk in Patients with Newly Diagnosed Multiple Myeloma Treated with Carfilzomib or Bortezomib in Combination with Lenalidomide and DexamethasoneBLOOD, 2022, 140 : 8550 - 8551Loncharich, Alexa J.Fiala, Mark A.Slade, Michael J.Vickroy, AngelaKavanaugh, MargaretWilson, KariSchroeder, Mark A.Stockerl-Goldstein, Keith E.Vij, RaviSanfilippo, Kristen M.
- [50] Lenalidomide and Dexamethasone Asymptomatic multiple Myeloma with high Risk of Disease ProgressionONKOLOGE, 2013, 19 (12): : 1076 - 1077Ahlborn, M.